Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
May 16, 2019
Mustang Bio and Nationwide Children’s Hospital Receive Orphan Drug Designation for MB-108 (Oncolytic Virus C134) for the Treatment of Malignant Glioma
NEW YORK and COLUMBUS, Ohio, May 16, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical ...
May 16, 2019
Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting
NEW YORK, May 16, 2019 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium") today announced that an abstract pertaining to its lead product candidate, Iomab-B, ...
May 16, 2019
NeuBase Therapeutics Designates Industry Leaders to Board of Directors
PITTSBURGH, May 16, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (“NeuBase”), a biotechnology company developing next generation antisense therapies to address genetic diseases, today announced ...
May 16, 2019
Genocea Announces Positive Interim Immunogenicity Data from GEN-009 Neoantigen Vaccine Phase 1/2a Clinical Trial
CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the first clinical results ...
May 16, 2019
CorMedix Inc. to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
BERKELEY HEIGHTS, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...
May 16, 2019
Cellectar Biosciences Announces $10.0 Million Financing
FLORHAM PARK, N.J., May 16, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization ...
May 16, 2019
Zealand Pharma initiates several Phase 3 studies and grows cash position in the first quarter of 2019
Copenhagen, May 16, 2019 – Zealand Pharma A/S (“Zealand”) (ZEAL) (CVR No. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and ...
May 16, 2019
Outlook Therapeutics started at outperform with $12 stock price target at Oppenheimer
Oppenheimer initiated coverage of Outlook Therapeutics Inc's stock on Thursday at a price target of $12, while giving it an outperform rating. It's a big ...
May 16, 2019
Aptose to Present New Preclinical Data for CG-806 at the 24th Congress of The European Hematology Association
SAN DIEGO and TORONTO, May 16, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing ...
May 16, 2019
Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating Lymphocyte) Products
CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced a research collaboration with ...
May 15, 2019
Kodiak Sciences Announces First Quarter 2019 Financial Results and Recent Business Highlights
PALO ALTO, Calif., May 15, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical-stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, ...
May 15, 2019
Lead Physicians in Pluristem’s Pivotal Study in Critical Limb Ischemia Publish Peer-Reviewed Paper
HAIFA, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (PSTI) (PSTI.TA), a leading regenerative medicine company developing novel placenta-based cell therapy products, announced ...
May 15, 2019
VBL Therapeutics Announces First Quarter 2019 Financial Results
TEL AVIV, Israel, May 15, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT) today announced financial results for the first quarter ended March 31, 2019, and ...
May 15, 2019
AC Immune Reports Q1 2019 Financial Results and Business Update
LAUSANNE, Switzerland, May 15, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on pioneering Precision ...
May 15, 2019
ProQR to Present at the RBC Capital Markets Healthcare Conference
LEIDEN, the Netherlands and CAMBRIDGE, Mass., May 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines ...
May 15, 2019
Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update
DURHAM, NC / ACCESSWIRE / May 15, 2019 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system ...
May 15, 2019
Krystal Biotech to Present at the RBC Capital Markets 2019 Healthcare Conference
PITTSBURGH, May 15, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announced that ...
May 15, 2019
Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019
CRANBURY, N.J., May 15, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”) today reported business highlights and financial results for its second fiscal ...
May 15, 2019
Vaccinex Reports First Quarter 2019 Financial Results and Provides Corporate Update
ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, ...
May 15, 2019
Vaccinex Announces Poster Presentations at the 2019 ASCO Annual Meeting
ROCHESTER, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, ...
Page 6 of 150